Skip to main content

Advertisement

SpringerLink
Log in

Skeletal related events in patients with bone metastasis arising from non-small cell lung cancer

  • Original Article
  • Published:
Supportive Care in Cancer Aims and scope Submit manuscript

Abstract

Purpose

The skeleton is one of the most common sites of metastasis in patients with non-small cell lung cancer (NSCLC). Metastasis increases the risk of skeletal-related events (SREs). The purpose of this study is to evaluate the incidence of SREs and the factors associated with the development of SREs in patients with bone metastases (BM) arising from NSCLC.

Methods

A cohort study was carried out involving 95 patients with BM associated with NSCLC who were enrolled between 2007 and 2011. Clinical and sociodemographic data were extracted from the physical and electronic records. The association between exposure variables and outcome (SREs) was assessed using crude odds ratio (OR). Survival analysis of patients with BM was conducted using the Kaplan-Meier method. A log-rank test was used to assess differences between the curves of those who did and did not experience SREs.

Results

Sixty-two out of 95 patients with BM (65.3 %) showed evidence of at least one SRE. Multiple analysis revealed that patients with a history of smoking (OR = 6.76; 95% CI = 1.3–33.0; p < 0.01), performance status ≥2 (OR = 3.38; 95% CI = 1.2–9.3; p < 0.01), and multiple BM (OR = 3.31; 95% CI = 1.1–9.9; p < 0.03) were at greater risk of SREs. Median survival time was 4.6 months (95% CI = 2.9–6.2) in patients who experienced SREs and 6.8 months (95% CI = 2.2–11.4) in patients who did not, a statistically significant difference (p = 0.03).

Conclusion

Patients with NSCLC are more likely to experience SREs if they have poor performance status, a history of smoking or multiple BM. Global survival was shorter in patients who suffer SREs.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Brasil. Instituto Nacional de Câncer (2014) Estimativa 2014: Incidência de Câncer no Brasil. http://www.inca.gov.br/. Accessed 10 Dec 2013

  2. Parkin DM, Bray F, Ferlay J et al (2001) Estimating the world cancer burden: GLOBOCAN 2000. Int J Cancer 94:153

    Article  PubMed  CAS  Google Scholar 

  3. Siegel R, Naishadham D, Jemal A (2013) Cancer statistics, 2013. CA Cancer J Clin 63(1):11–30

    Article  PubMed  Google Scholar 

  4. Kohler BA, Wand E, McCarthy BJ et al (2011) Annual report to the nation on the status of cancer, 1975–2007, featuring tumors of the brain and other nervous system. J Natl Cancer Inst 103:714–736

    Article  PubMed  PubMed Central  Google Scholar 

  5. Hirsh V (2009) Skeletal disease contributes substantially to morbidity and mortality in patients with lung cancer. Clin Lung Cancer 10(4):223–229

    Article  PubMed  Google Scholar 

  6. Roodman GD (2004) Mechanisms of bone metastasis. N Engl J Med 350:1655–1664

    Article  PubMed  CAS  Google Scholar 

  7. Al Husaini H, Wheatley-Price P, Clemons M et al (2009) Prevention and management of bone metastases in lung cancer: a review. J Thorac Oncol 4:251–259

    Article  PubMed  Google Scholar 

  8. Coleman RE (2001) Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 27:165–176

    Article  PubMed  CAS  Google Scholar 

  9. Coleman RE (1997) Skeletal complications of malignancy. Cancer 80:1588–1594

    Article  PubMed  CAS  Google Scholar 

  10. Coleman RE (2004) Bisphosphonates: clinical experience. Oncologist 9(suppl 4):14–27

    Article  PubMed  CAS  Google Scholar 

  11. Tsuya A, Kurata T, Tamura K et al (2007) Skeletal metastases in non-small cell lung cancer: a retrospective study. Lung Cancer 57(2):229–232

    Article  PubMed  Google Scholar 

  12. Hoefeler H, Duran I, Hechmati G et al (2014) Health resource utilization associated with skeletal-related events in patients with bone metastases: Results from a multinational retrospective–prospective observational study—a cohort from 4 European countries. J Bone Oncol 3(2):40–48

    Article  Google Scholar 

  13. Mu Sun J, Ahn JS, Lee S et al (2011) Predictors of skeletal-related events in non-small cell lung cancer patients with bone metastases. Lung Cancer 71(1):89–93

    Article  Google Scholar 

  14. Decroisette C, Monnet I, Berard H et al (2011) Epidemiology and treatment costs of bone metastases from lung cancer: a French prospective, observational, multicenter study. J Thorac Oncol 6(3):573–582

    Article  Google Scholar 

  15. Oster G, Lamerato L, Glass AG et al (2013) Natural history of skeletal-related events in patients with breast, lung, or prostate cancer and metastases to bone: a 15-year study in two large US health systems. Support Care Cancer 21(12):3279–3286

    Article  PubMed  Google Scholar 

  16. Bae HM, Lee SH, Kim TM et al (2012) Prognostic factors for non-small cell lung cancer with bone metastasis at the time diagnosis. Lung Cancer 77(3):572–577

    Article  PubMed  Google Scholar 

  17. Sathiakumar N, Delzell E, Morrisey MA et al (2013) Mortality following bone metastasis and skeletal-related events among patients 65 years and above with lung cancer: a population-based analysis of U.S Medicare beneficiaries, 1999–2006. Lung Ind 30(1):20–26

    Article  Google Scholar 

  18. De Marini F, Eberhardt W, Harper PG et al (2009) Bisphosphonate use in patients with lung cancer and bone metastases: recommendations of a European expert panel. J Thorac Oncol 4(10):1280–1288

    Article  Google Scholar 

  19. Wei J, Jun T, Pinghai Z et al (2011) Factors associated with the development of skeletal-related events in non-small cell lung cancer patients with bone metastases. Int J Radiat Oncol Biol Phys 81(2):S596

    Article  Google Scholar 

  20. Katakami N, Kunikane H, Takeda K et al (2014) Prospective study on the incidence of bone metastasis (BM) and skeletal-related events (SREs) in patients (pts) with stage IIIB and IV lung cancer-CSP-HOR 13. J Thorac Oncol 9(2):231–238

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  21. Nagata M, Kudoh S, Mitsuoka S et al (2013) Skeletal-related events in advanced lung adenocarcinoma patients evaluated EGFR mutations. Osaka City Med J 59(1):45–52

    PubMed  Google Scholar 

  22. Cetin K, Christiansen CF, Jacobsen JB, NØrgarrd M, SØrensen HT (2014) Bone metastasis, skeletal-related events, and mortality in lung cancer patients: a Danish population-based cohort study. Lung Cancer 86(2):247–254

    Article  PubMed  Google Scholar 

  23. Rosen LS, Gordon D, Tchekmedyian NS, Yanagihara R, Hirsh V, Krazakowski M, Pawlicki M, De Souza P, Zheng M, Urbanowitz G, Reitsma D, Seaman J (2004) Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with non-small cell lung carcinoma and other solid tumors: a randomized, phase III, double-blind, placebo-controlled trial. Cancer 100:2613–2621

    Article  PubMed  CAS  Google Scholar 

  24. Peddi P, Lopez-Olivo MA, Pratt GF, Suarez-Almazor ME (2013) Denosumab in patients with cancer and skeletal metastases: a systematic review and meta-analysis. Cancer Treat Rev 39(1):97–104

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  25. Lipton A, Fizazi K, Stopeck AT, Henry DA, Brown JE, Yardley DA, Richardson GA, Siena S, Maroto P, Clemens M, Bilynskyy B, Charu V, Beuzeboc P, Rader M, Viniegra M, Saad F, Ke C, Braun SJ (2012) Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. Eur J Cancer 48(16):3082–3092

    Article  PubMed  CAS  Google Scholar 

  26. Ford J, Cummins E, Sharma P, Elders A, Stewart F, Johnston R, Royle P, Jones R, Mulatero C, Todd R, Mowatt G (2013) Systematic review of the clinical effectiveness and cost-effectiveness, and economic evaluation, of denosumab for the treatment of bone metastases from solid tumours. Health Technol Assess 17(29):1–386

    Article  PubMed  CAS  Google Scholar 

  27. Wang Z, Qiao D, Lu Y, Curtis D, Wen X, Yao Y, Zhao H (2015) Systematic literature review and network meta-analysis comparing bone-targeted agents for the prevention of sketetal-related events in cancer patients with bone metastasis. Oncologist 20(4):440–449

    Article  PubMed  CAS  Google Scholar 

  28. Lopez-Olivo MA, Shah NA, Pratt G et al (2012) Bisphosphonates in the treatment of patients with lung cancer and metastatic bone disease: a systematic review and meta-analysis. Support Care Cancer 20(11):2985–2998

    Article  PubMed  PubMed Central  Google Scholar 

  29. Henry D, Vadhan-Raj S, Hirsh V, Von Moos R, Hungria V, Costa L, Woll PJ, Scagliotti G, Smith G, Feng A, Jun S, Dansey R, Yeh H (2014) Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors. Support Care Cancer 22(3):679–687

    Article  PubMed  Google Scholar 

  30. Sekine I, Nokihara H, Yamamoto N et al (2009) Risk factors for skeletal-related events in patients with non-small cell lung cancer treated by chemotherapy. Lung Cancer 65(2):219–222

    Article  PubMed  Google Scholar 

  31. Ward KD, Klesges RC (2001) A meta-analysis of the effects of cigarette smoking on bone mineral density. Calcif Tissue Int 68:259–270

    Article  PubMed  CAS  Google Scholar 

  32. Williams AR, Weiss NS, Ure CL et al (1982) Effect of weight, smoking, and estrogen use on the risk of hip and forearm fractures in postmenopausal women. Obstet Gyncecol 60:695–699

    CAS  Google Scholar 

  33. Oster G, Lamerato L, Glass AG, Richert-Boe KE, Lopez A, Chung K, Richhariya A, Dodge T, Wolff GG, Balakumaran A, Edelsberg J (2014) Use of intravenous bisphosphonates in patients with breast, lung, or prostate cancer and metastases to bone: a 15-year study in two large US health systems. Support Care Cancer 22(4):1363–1373

    Article  PubMed  Google Scholar 

Download references

Conflict of Interest

The authors declare that they have no competing interests.

Consent to Participate

For this type of study informed consent is not required.

Author information

Authors and Affiliations

  1. National Cancer Institute and Federal University of the State of Rio de Janeiro, Rio de Janeiro, Brazil

    Gustavo Telles da Silva & Luiz Claudio Santos Thuler

  2. National Cancer Institute and Augusto Motta University Center, Rio de Janeiro, Brazil

    Anke Bergmann

  3. Instituto Nacional de Câncer-Coordenação de Pesquisa Clínica, Rua André Cavalcanti, 37 / 2o andar, Centro-Rio de Janeiro, RJ, 20231-050, Brazil

    Luiz Claudio Santos Thuler

Authors
  1. Gustavo Telles da Silva
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Anke Bergmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Luiz Claudio Santos Thuler
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Luiz Claudio Santos Thuler.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

da Silva, G.T., Bergmann, A. & Thuler, L.C.S. Skeletal related events in patients with bone metastasis arising from non-small cell lung cancer. Support Care Cancer 24, 731–736 (2016). https://doi.org/10.1007/s00520-015-2835-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00520-015-2835-1

Keywords

Search

Navigation